DK0861236T4 - Cykliske og heterocykliske N-substituerede alphaiminohydroxam- og carboxylsyrer - Google Patents
Cykliske og heterocykliske N-substituerede alphaiminohydroxam- og carboxylsyrerInfo
- Publication number
- DK0861236T4 DK0861236T4 DK96938052T DK96938052T DK0861236T4 DK 0861236 T4 DK0861236 T4 DK 0861236T4 DK 96938052 T DK96938052 T DK 96938052T DK 96938052 T DK96938052 T DK 96938052T DK 0861236 T4 DK0861236 T4 DK 0861236T4
- Authority
- DK
- Denmark
- Prior art keywords
- heterocyclic
- cyclic
- carboxylic acids
- substituted alpha
- amino hydroxamic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE1995142189 DE19542189A1 (de) | 1995-11-13 | 1995-11-13 | Cyclische N-substituierte alpha-Iminohydroxamsäuren |
DE1996112298 DE19612298A1 (de) | 1996-03-28 | 1996-03-28 | Heterocyclische N-substituierte alpha-Iminohydroxamsäuren |
PCT/EP1996/004776 WO1997018194A1 (fr) | 1995-11-13 | 1996-11-04 | ACIDES α-IMINOHYDROXAMIQUES ET CARBOXILIQUES CYCLIQUES ET HETEROCYCLIQUES SUBSTITUES EN POSITION N |
Publications (2)
Publication Number | Publication Date |
---|---|
DK0861236T3 DK0861236T3 (da) | 2002-05-21 |
DK0861236T4 true DK0861236T4 (da) | 2006-12-18 |
Family
ID=26020318
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK96938052T DK0861236T4 (da) | 1995-11-13 | 1996-11-04 | Cykliske og heterocykliske N-substituerede alphaiminohydroxam- og carboxylsyrer |
Country Status (20)
Country | Link |
---|---|
US (3) | US6207672B1 (fr) |
EP (1) | EP0861236B2 (fr) |
JP (1) | JP4638560B2 (fr) |
KR (1) | KR100475206B1 (fr) |
CN (1) | CN1131215C (fr) |
AT (1) | ATE213232T1 (fr) |
AU (1) | AU707707B2 (fr) |
BR (1) | BR9611479B1 (fr) |
CA (1) | CA2237590C (fr) |
CZ (1) | CZ297550B6 (fr) |
DE (1) | DE59608740D1 (fr) |
DK (1) | DK0861236T4 (fr) |
ES (1) | ES2170884T5 (fr) |
HU (1) | HU223086B1 (fr) |
MX (1) | MX9803753A (fr) |
PL (1) | PL186869B1 (fr) |
PT (1) | PT861236E (fr) |
RU (1) | RU2164914C2 (fr) |
TR (1) | TR199800849T2 (fr) |
WO (1) | WO1997018194A1 (fr) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0874830T3 (da) * | 1995-12-08 | 2003-04-22 | Agouron Pharma | Metalloproteinaseinhibitor, farmaceutisk præparat indeholdende denne og den farmaceutiske anvendelse samt en fremgangsmåde til fremstilling deraf |
US6500948B1 (en) | 1995-12-08 | 2002-12-31 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof |
FR2748026B1 (fr) * | 1996-04-26 | 1998-06-05 | Adir | Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
DK0923561T3 (da) * | 1996-08-28 | 2003-02-24 | Procter & Gamble | Heterocykliske metalloproteaseinhibitorer |
US5977408A (en) * | 1996-10-16 | 1999-11-02 | American Cyanamid Company | Preparation and use of β-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
US6228869B1 (en) | 1996-10-16 | 2001-05-08 | American Cyanamid Company | Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
US5962481A (en) * | 1996-10-16 | 1999-10-05 | American Cyanamid Company | Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
US6548524B2 (en) | 1996-10-16 | 2003-04-15 | American Cyanamid Company | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
US5929097A (en) * | 1996-10-16 | 1999-07-27 | American Cyanamid Company | Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
AU4812697A (en) * | 1996-10-22 | 1998-05-15 | Pharmacia & Upjohn Company | Alpha-amino sulfonyl hydroxamic acids as matrix metalloproteinase inhibitors |
US6174915B1 (en) | 1997-03-25 | 2001-01-16 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
US6008243A (en) * | 1996-10-24 | 1999-12-28 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use |
TW464652B (en) | 1996-10-30 | 2001-11-21 | Tanabe Seiyaku Co | S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof |
AU730127B2 (en) * | 1997-01-23 | 2001-02-22 | Agouron Pharmaceuticals, Inc. | Sulfamide-metalloprotease inhibitors |
US6376506B1 (en) | 1997-01-23 | 2002-04-23 | Syntex (U.S.A.) Llc | Sulfamide-metalloprotease inhibitors |
ZA98376B (en) * | 1997-01-23 | 1998-07-23 | Hoffmann La Roche | Sulfamide-metalloprotease inhibitors |
US5985900A (en) * | 1997-04-01 | 1999-11-16 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
DE19719817A1 (de) * | 1997-05-13 | 1998-11-19 | Hoechst Ag | Substituierte 6- und 7-Aminotetrahydroisochinolincarbonsäuren |
EP1003751A1 (fr) * | 1997-08-04 | 2000-05-31 | Amgen Inc. | Inhibiteurs de metalloproteases heterocycliques hybrides et substitues par de l'acide hydroxamique |
KR20010030935A (ko) * | 1997-10-06 | 2001-04-16 | 윌리암 에이취 캘넌, 에곤 이 버그 | 매트릭스 메탈로프로테이나제 및 종양괴사인자-α 전환효소 억제제로서의 오르토-설폰아미도 바이사이클릭헤테로아릴 하이드록삼산의 제조 및 용도 |
US6130220A (en) * | 1997-10-16 | 2000-10-10 | Syntex (Usa) Inc. | Sulfamide-metalloprotease inhibitors |
FR2771095B1 (fr) * | 1997-11-14 | 1999-12-17 | Adir | Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US6107291A (en) * | 1997-12-19 | 2000-08-22 | Amgen Inc. | Azepine or larger medium ring derivatives and methods of use |
US6335329B1 (en) | 1997-12-19 | 2002-01-01 | Amgen Inc. | Carboxylic acid substituted heterocycles, derivatives thereof and methods of use |
CN1293663A (zh) * | 1998-01-27 | 2001-05-02 | 美国氰胺公司 | 为基质金属蛋白酶抑制剂的2,3,4,5-四氢-1h-[1,4]苯并二氮杂䓬-3-异羟肟酸 |
US6071903A (en) * | 1998-01-27 | 2000-06-06 | American Cyanamid Company | 2,3,4,5-tetrahydro-1H-[1,4]-benzodiazepine-3-hydroxyamic acids |
WO1999058531A1 (fr) * | 1998-05-14 | 1999-11-18 | Du Pont Pharmaceuticals Company | Nouveaux acides hydroxamiques a substitution aryle en tant qu'inhibiteurs de metalloproteinase |
WO2000023443A1 (fr) * | 1998-10-22 | 2000-04-27 | Akzo Nobel N.V. | Derives de tetrahydropyridopyridine, et produits intermediaires permettant de produire lesdits derives |
US20040122011A1 (en) * | 1998-12-23 | 2004-06-24 | Pharmacia Corporation | Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy |
CN1178915C (zh) | 1999-01-27 | 2004-12-08 | 惠氏控股有限公司 | 含有炔基的异羟肟酸衍生物、其制备及其作为基质金属蛋白酶抑制剂/TNF-α转变酶抑制剂的用途 |
US6277885B1 (en) | 1999-01-27 | 2001-08-21 | American Cyanamid Company | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6340691B1 (en) | 1999-01-27 | 2002-01-22 | American Cyanamid Company | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors |
US6753337B2 (en) | 1999-01-27 | 2004-06-22 | Wyeth Holdings Corporation | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors |
US6225311B1 (en) | 1999-01-27 | 2001-05-01 | American Cyanamid Company | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors |
US6762178B2 (en) | 1999-01-27 | 2004-07-13 | Wyeth Holdings Corporation | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6200996B1 (en) | 1999-01-27 | 2001-03-13 | American Cyanamid Company | Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors |
AR022423A1 (es) * | 1999-01-27 | 2002-09-04 | American Cyanamid Co | Compuestos derivados de acidos 2,3,4,5-tetrahidro-1h-[1,4]benzodiazepina-3-hidroxamicos, composicion farmaceutica que los comprenden, y el uso de losmismos para la manufactura de un medicamento |
US6313123B1 (en) | 1999-01-27 | 2001-11-06 | American Cyanamid Company | Acetylenic sulfonamide thiol tace inhibitors |
US6544984B1 (en) | 1999-01-27 | 2003-04-08 | American Cyanamid Company | 2,3,4,5-tetrahydro-1H-(1,4)benzodiazepine-3-hydroxamic acids |
US6326516B1 (en) | 1999-01-27 | 2001-12-04 | American Cyanamid Company | Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6946473B2 (en) | 1999-01-27 | 2005-09-20 | Wyeth Holdings Corporation | Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors |
GB9903598D0 (en) * | 1999-02-18 | 1999-04-07 | Univ Manchester | Connective tissue healing |
GT200000203A (es) | 1999-12-01 | 2002-05-24 | Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas. | |
GB0011409D0 (en) * | 2000-05-11 | 2000-06-28 | Smithkline Beecham Plc | Novel compounds |
MXPA01013172A (es) | 2001-02-14 | 2002-08-21 | Warner Lambert Co | Inhibidores sulfonamida de metaloproteinasa de matriz. |
FR2821842B1 (fr) * | 2001-03-07 | 2003-05-09 | Servier Lab | Nouveaux derives d'inhibiteurs de mettalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US6770647B2 (en) | 2001-08-17 | 2004-08-03 | Bristol-Myers Squibb Pharma Company | Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) |
BR0213736A (pt) | 2001-11-01 | 2004-10-19 | Wyeth Corp | ácidos hidroxâmicos de sulfonamida de arila alênica como metaloproteinase matriz e inibidores de tace |
US6716853B2 (en) | 2002-03-02 | 2004-04-06 | Aventis Pharma Deutschland Gmbh | Cyclic N-substituted alpha-imino carboxylic acids for selective inhibition of collogenase |
DE10209299A1 (de) | 2002-03-02 | 2003-09-18 | Aventis Pharma Gmbh | Cyclische N-substituierte alpha-Iminocarbonsäuren zur selektiven Inhibierung von Kollagenase |
AU2003304456A1 (en) * | 2002-12-23 | 2005-03-16 | Wyeth Holdings Corporation | Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors |
WO2004060892A1 (fr) * | 2002-12-27 | 2004-07-22 | Japan Tobacco Inc. | Composes heterocycliques contenant n condense et leur utilisation medicale |
DE10300015A1 (de) * | 2003-01-03 | 2004-07-15 | Aventis Pharma Deutschland Gmbh | Iminosäurederivate als Inhibitoren von Matrix-Metallproteinasen |
US7205315B2 (en) | 2003-09-27 | 2007-04-17 | Sanofi-Aventis Deutschland Gmbh | Bicyclic imino acid derivatives as inhibitors of matrix metalloproteinases |
DE10344936A1 (de) | 2003-09-27 | 2005-04-21 | Aventis Pharma Gmbh | Bicyclische Iminosäurederivate als Inhibitoren von Matrix-Metalloproteinasen |
DE10351904A1 (de) * | 2003-11-06 | 2005-06-09 | Aventis Pharma Deutschland Gmbh | Verfahren zur Herstellung von cyclischen N-substituierten alpha-Iminocarbonsäure |
US7244845B2 (en) * | 2003-11-06 | 2007-07-17 | Sanofi-Aventis Deutschland Gmbh | Process for preparing cyclic N-substituted alpha-imino carboxylic acids |
DE102004004974A1 (de) * | 2004-01-31 | 2005-08-18 | Aventis Pharma Deutschland Gmbh | Thieno-Iminosäure-Derivate als Inhibitoren von Matrix-Metalloproteinasen |
US7705017B2 (en) * | 2004-05-03 | 2010-04-27 | En Vivo Pharmaceuticals, Inc. | Compounds for treatment of neurodegenerative diseases |
DE102004031850A1 (de) * | 2004-06-30 | 2006-01-26 | Sanofi-Aventis Deutschland Gmbh | Substituirte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
DE102004031620A1 (de) * | 2004-06-30 | 2006-02-02 | Sanofi-Aventis Deutschland Gmbh | 4-Trifluormethoxyphenoxybenzol-4`-sulfonsäuren, Verfahren zu ihrer Herstellung und Verwendung in Arzneimitteln |
US7601838B2 (en) * | 2004-12-28 | 2009-10-13 | Council Of Scientific And Industrial Research | 2-Alkyl/aryl sulphonyl-1,2,3,4-tetrahydro-9H-pyrido (3,4-b) indole-3-carboxylic acid esters/amides useful as antithrombotic agents |
DE102005002500A1 (de) * | 2005-01-19 | 2006-07-27 | Sanofi-Aventis Deutschland Gmbh | Tetrahydrofuranderivate als Inhibitoren von Matrix-Metalloproteinasen |
DE102005015040A1 (de) * | 2005-03-31 | 2006-10-05 | Sanofi-Aventis Deutschland Gmbh | Substituierte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
KR101329437B1 (ko) | 2005-05-13 | 2013-11-14 | 토포타겟 유케이 리미티드 | Hdac 억제제의 약학 제형 |
WO2007045661A1 (fr) * | 2005-10-20 | 2007-04-26 | Nordic Bioscience Diagnostics A/S | Détection ou quantification d'aggrecane et de fragments de celui-ci |
GB0526257D0 (en) * | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
WO2007141029A1 (fr) * | 2006-06-08 | 2007-12-13 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) | Inhibiteurs spécifiques de protéase et leur utilisation pour le traitement du cancer |
EP2182810B1 (fr) | 2007-08-03 | 2017-11-08 | Nucitec S.A. de C.V. | Compositions et procédés de traitement et de prévention de l'ostéoarthrite |
US8293913B2 (en) | 2007-08-07 | 2012-10-23 | Abbott Gmbh & Co. Kg | Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin-5-HT6 receptor |
EP2231596A4 (fr) | 2007-12-14 | 2012-06-06 | Univ Georgetown | Inhibiteurs de l'histone déacétylase |
WO2009131065A1 (fr) * | 2008-04-24 | 2009-10-29 | 萬有製薬株式会社 | Inhibiteur d'enzyme d'allongement d'acide gras à longue chaîne incluant un dérivé arylsulfonylé en tant que principe actif |
EA201100187A1 (ru) | 2008-07-14 | 2011-10-31 | Новартис Аг | Селективные ингибиторы ммр-12 и ммр-13 на основе гидроксамовой кислоты |
FR2947270B1 (fr) | 2009-06-30 | 2011-08-26 | Galderma Res & Dev | Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique |
FR2947268B1 (fr) | 2009-06-30 | 2011-08-26 | Galderma Res & Dev | Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique |
US20140275108A1 (en) | 2013-03-15 | 2014-09-18 | Galderma Research & Development | Novel benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics |
US20190008828A1 (en) | 2015-12-28 | 2019-01-10 | The U.S.A., As Represented By The Secretary Department Of Health And Human Services | Methods for inhibiting human immunodeficiency virus (hiv) release from infected cells |
ES2695533T3 (es) | 2016-02-01 | 2019-01-08 | Galderma Res & Dev | Compuestos de bencenosulfonamida, método para su síntesis y uso de los mismos en medicina y cosméticos |
WO2019102488A1 (fr) | 2017-11-27 | 2019-05-31 | Council Of Scientific & Industrial Research | Dérivés d'indole (sulfomyl) n-hydroxy benzamide en tant qu'inhibiteurs sélectifs de hdac |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES391542A1 (es) * | 1970-06-02 | 1975-09-16 | Hokuriku Pharmaceutical | Un procedimiento para la preparacion de nuevos derivados de isoquinobenzodiazepina. |
TW201303B (fr) | 1990-07-05 | 1993-03-01 | Hoffmann La Roche | |
JPH04210675A (ja) † | 1990-12-13 | 1992-07-31 | Otsuka Pharmaceut Co Ltd | ベンゼン誘導体 |
US5219851A (en) * | 1991-03-05 | 1993-06-15 | Warner-Lambert Company | Tetrahydroisoquinoline-type renin inhibiting peptides |
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
US5506242A (en) † | 1993-01-06 | 1996-04-09 | Ciba-Geigy Corporation | Arylsufonamido-substituted hydroxamic acids |
FR2701480B1 (fr) | 1993-02-15 | 1995-05-24 | Sanofi Elf | Composés à groupe sulfamoyle et amidino, leur procédé de préparation et les compositions pharmaceutiques les contenant. |
DK0766665T3 (da) † | 1994-06-22 | 1999-12-06 | British Biotech Pharm | Metalloproteinaseinhibitorer |
DE10003007C2 (de) * | 2000-01-25 | 2002-06-13 | Schunk Metall & Kunststoff | Erdungskontakt |
-
1996
- 1996-11-04 BR BRPI9611479-7A patent/BR9611479B1/pt not_active IP Right Cessation
- 1996-11-04 KR KR10-1998-0703715A patent/KR100475206B1/ko not_active IP Right Cessation
- 1996-11-04 EP EP96938052A patent/EP0861236B2/fr not_active Expired - Lifetime
- 1996-11-04 TR TR1998/00849T patent/TR199800849T2/xx unknown
- 1996-11-04 AU AU75624/96A patent/AU707707B2/en not_active Ceased
- 1996-11-04 CN CN96198294A patent/CN1131215C/zh not_active Expired - Fee Related
- 1996-11-04 JP JP51854297A patent/JP4638560B2/ja not_active Expired - Fee Related
- 1996-11-04 HU HU9903405A patent/HU223086B1/hu not_active IP Right Cessation
- 1996-11-04 DE DE59608740T patent/DE59608740D1/de not_active Expired - Lifetime
- 1996-11-04 AT AT96938052T patent/ATE213232T1/de active
- 1996-11-04 PL PL96326702A patent/PL186869B1/pl not_active IP Right Cessation
- 1996-11-04 ES ES96938052T patent/ES2170884T5/es not_active Expired - Lifetime
- 1996-11-04 WO PCT/EP1996/004776 patent/WO1997018194A1/fr active IP Right Grant
- 1996-11-04 PT PT96938052T patent/PT861236E/pt unknown
- 1996-11-04 RU RU98111153/04A patent/RU2164914C2/ru not_active IP Right Cessation
- 1996-11-04 CZ CZ0145398A patent/CZ297550B6/cs not_active IP Right Cessation
- 1996-11-04 CA CA2237590A patent/CA2237590C/fr not_active Expired - Fee Related
- 1996-11-04 US US09/068,497 patent/US6207672B1/en not_active Expired - Lifetime
- 1996-11-04 DK DK96938052T patent/DK0861236T4/da active
-
1998
- 1998-05-12 MX MX9803753A patent/MX9803753A/es unknown
-
2001
- 2001-02-12 US US09/780,514 patent/US6573277B2/en not_active Expired - Fee Related
-
2003
- 2003-03-03 US US10/376,287 patent/US6815440B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0861236T4 (da) | Cykliske og heterocykliske N-substituerede alphaiminohydroxam- og carboxylsyrer | |
NO990279D0 (no) | Isobutylgaba og dets derivater for behandling av smerte | |
NO924433L (no) | Isoksazol-4-karboksylsyreamider og hydroksyalkyliden-cyaneddiksyreamider, legemidler inneholdende disse forbindelsene og deres anvendelse | |
NO963499L (no) | Hydroksaminsyre- og karboksylsyrederivater, fremgangsmåte for deres fremstilling og anvendelse derav | |
ATE427300T1 (de) | Heterocyclisch substituierte amide als calpainhemmer | |
BR9810841A (pt) | Inibidores de metaloprotease alicìclicos | |
DK1194425T3 (da) | Substituerede benzimidazoler | |
NO20030724D0 (no) | Anvendelse av derivater av valproinsyreamider og 2- valproensyreamider for terapi eller prevensjon av smerte- og/eller hodepinelidelser | |
DK1030836T3 (da) | Hydroxam- og carboxylsyrederivater der har MMP- og TNF-inhiberende aktivitet | |
DK0490772T3 (da) | 1,4-disubstituerede piperaziner, fremgangsmåde til fremstilling heraf og farmaceutiske midler, der indeholder dem | |
DE602004004665D1 (en) | Acetylenderivate als inhibitoren von histondeacetylase | |
DK1546127T3 (da) | Nye pyrimidinamidderivater og anvendelse deraf | |
NO20000784D0 (no) | Nye aggrecanaseinhibitorer og matriksmetalloproteinaser for behandling av artritt | |
DE69613693T2 (de) | 2-heteroarylalkenylderivate der cyclopentano-heptan(heptaen)säure als therapeutisches mittel zur behandlung des erhöhten augeninnendruckes | |
DE69511240T2 (de) | Derivate des hydroxamsäure als metalloproteinaseinhibitoren | |
CY1106155T1 (el) | Χρηση παραγωγων 3-βενζολοφαινυλοξικων οξεων για την αντιμετωπιση διαταραχων του αμφιβληστροειδους | |
YU48698A (sh) | Karboksamidni derivati pirolidina, piperidina i heksahidroazepina za lečenje oboljenja na bazi tromboze | |
ATE292109T1 (de) | Substituierte benzamide als inhibitoren von rhinovirus 3c protease | |
DE69500673D1 (de) | Arzneimittel zur therapeutischen und prophylaktischen Behandlung von Krankheiten, die durch Hyperplasie der glatten Muskelzellen bedingt sind | |
ATE225171T1 (de) | Aminosäurederivate zur behandlung von schlaganfall | |
DE69531044D1 (de) | Behandlung von entzündung durch die gabe von spezifischen sulfatase-enzymen und/oder inhibitoren der sulfatierung | |
HUP0203118A2 (hu) | Béta-diszubsztituált metalloproteáz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
DK1042288T3 (da) | Tripeptidyl-peptidase inhibitorer | |
ATE81971T1 (de) | Synergistische kombination von decarboxylasehemmern und l-dopa-pellets. | |
ES2160102T3 (es) | Tratamiento del eritema provocado por uv. |